Work

Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.

Year: 2008

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v112.11.1944.1944

Authors: Geoffrey L. Uy, Michael P. Rettig, Kyle M. McFarland, Lindsay M. Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith Stockerl-Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio

Institution: Washington University in St. Louis

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2558221616

FWCI: 1.94

Cites:

Cited by: 12

Related to: 10